These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 16421149)

  • 1. Case reports of suspected adverse drug reactions--systematic literature survey of follow-up.
    Loke YK; Price D; Derry S; Aronson JK
    BMJ; 2006 Feb; 332(7537):335-9. PubMed ID: 16421149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unity from diversity: the evidential use of anecdotal reports of adverse drug reactions and interactions.
    Aronson JK
    J Eval Clin Pract; 2005 Apr; 11(2):195-208. PubMed ID: 15813716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Case reports of suspected adverse drug reactions: case reports generate signals efficiently.
    Russmann S
    BMJ; 2006 Feb; 332(7539):488. PubMed ID: 16497771
    [No Abstract]   [Full Text] [Related]  

  • 4. Patient reporting of suspected adverse drug reactions: a review of published literature and international experience.
    Blenkinsopp A; Wilkie P; Wang M; Routledge PA
    Br J Clin Pharmacol; 2007 Feb; 63(2):148-56. PubMed ID: 17274788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spontaneously reported fatal suspected adverse drug reactions: a 10-year survey from Sweden.
    Wester K; Jönsson A; Spigset O; Hägg S
    Pharmacoepidemiol Drug Saf; 2007 Feb; 16(2):173-80. PubMed ID: 16739241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse drug effects: evaluation of four secondary reference sources.
    Lyon RA
    Hosp Formul; 1985 Mar; 20(3):315-7, 320-1. PubMed ID: 10270307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
    Wysowski DK; Swartz L
    Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Making the most of spontaneous adverse drug reaction reporting.
    Waller PC
    Basic Clin Pharmacol Toxicol; 2006 Mar; 98(3):320-3. PubMed ID: 16611209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The quality of published adverse drug event reports.
    Kelly WN
    Ann Pharmacother; 2003 Dec; 37(12):1774-8. PubMed ID: 14632590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surveillance of suspected adverse reactions to natural health products in Italy.
    Menniti-Ippolito F; Mazzanti G; Santuccio C; Moro PA; Calapai G; Firenzuoli F; Valeri A; Raschetti R
    Pharmacoepidemiol Drug Saf; 2008 Jun; 17(6):626-35. PubMed ID: 18327867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Publications on adverse reactions to drugs in Spanish pediatric journals between 1980 and 1984].
    Morales Olivas FJ; Carpi Lobatón R
    An Esp Pediatr; 1989 Feb; 30(2):116-8. PubMed ID: 2719411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How has the impact of 'care pathway technologies' on service integration in stroke care been measured and what is the strength of the evidence to support their effectiveness in this respect?
    Allen D; Rixson L
    Int J Evid Based Healthc; 2008 Mar; 6(1):78-110. PubMed ID: 21631815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug associated hepatic reactions in New Zealand: 21 years experience.
    Pillans PI
    N Z Med J; 1996 Aug; 109(1028):315-9. PubMed ID: 8816722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence in pharmacovigilance: extracting adverse drug reactions articles from MEDLINE to link them to case databases.
    Garcelon N; Mougin F; Bousquet C; Burgun A
    Stud Health Technol Inform; 2006; 124():528-33. PubMed ID: 17108572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Case reports in anesthesiology: their trend through 17 years.
    De Amici D; Carrà C; Ceriana P; Gabutti G; Ramajoli F
    Acta Anaesthesiol Belg; 2000; 51(1):43-50. PubMed ID: 10806522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Food and Drug Administration monitoring of adverse drug reactions.
    Sills JM; Tanner LA; Milstien JB
    Am J Hosp Pharm; 1986 Nov; 43(11):2764-70. PubMed ID: 3799612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contribution of Latin America to pharmacovigilance.
    González JC; Arango VE; Einarson TR
    Ann Pharmacother; 2006; 40(7-8):1394-99. PubMed ID: 16868216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk management in dermatology: an analysis of data available from several British-based reporting systems.
    Gawkrodger DJ
    Br J Dermatol; 2011 Mar; 164(3):537-43. PubMed ID: 21143464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Adverse or toxic effects of drugs in medical practice: a one-year follow-up].
    Grange JC
    Therapie; 1990; 45(4):331-4. PubMed ID: 2399517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of adverse drug reactions on length of stay in surgical intensive care units.
    Vargas E; Terleira A; Hernando F; Perez E; Cordón C; Moreno A; Portolés A
    Crit Care Med; 2003 Mar; 31(3):694-8. PubMed ID: 12626971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.